SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-24-038681
Filing Date
2024-03-29
Accepted
2024-03-29 16:24:38
Documents
74
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K antx-20231231.htm   iXBRL 10-K 2460160
2 EX-10.3 antx-ex10_3.htm EX-10.3 305722
3 EX-10.5 antx-ex10_5.htm EX-10.5 76237
4 EX-10.6 antx-ex10_6.htm EX-10.6 153103
5 EX-23.1 antx-ex23_1.htm EX-23.1 5481
6 EX-31.1 antx-ex31_1.htm EX-31.1 14240
7 EX-31.2 antx-ex31_2.htm EX-31.2 14013
8 EX-32.1 antx-ex32_1.htm EX-32.1 8297
9 EX-32.2 antx-ex32_2.htm EX-32.2 8289
10 EX-97.1 antx-ex97_1.htm EX-97.1 57581
11 GRAPHIC img91092122_0.jpg GRAPHIC 34440
  Complete submission text file 0000950170-24-038681.txt   9448568

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT antx-20231231.xsd EX-101.SCH 1196778
78 EXTRACTED XBRL INSTANCE DOCUMENT antx-20231231_htm.xml XML 1251240
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

IRS No.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-41331 | Film No.: 24804379
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)